Applied BioCode Cash Flow-to-Debt Ratio
Applied BioCode cash flow-to-debt ratio. Applied BioCode (6598) has a Cash Flow-to-Debt Ratio of -0.06x as of September 2025, meaning its operating cash flow of NT$-19.88 Million could theoretically repay 0% of its total liabilities (NT$343.23 Million) in one year. Check Applied BioCode cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Applied BioCode (2013–2024)
Cash flow-to-debt ratio of Applied BioCode from 2013 to 2024. Historical debt coverage capacity for Applied BioCode across 12 annual periods. Check 6598 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Applied BioCode Cash Flow-to-Debt Ratio by Year (2013–2024)
Applied BioCode cash flow-to-debt ratio by year from 2013 to 2024. Year-by-year debt coverage analysis for Applied BioCode. For the full cash flow conversion analysis, see cash flow conversion of Applied BioCode.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.62x | NT$-207.74 Million | NT$336.07 Million | ▼ -0.1% |
| 2023 | -0.62x | NT$-205.09 Million | NT$332.22 Million | ▼ -267.7% |
| 2022 | 0.37x | NT$145.87 Million | NT$396.38 Million | ▲ +128.1% |
| 2021 | -1.31x | NT$-151.77 Million | NT$116.01 Million | ▼ -25.0% |
| 2020 | -1.05x | NT$-146.74 Million | NT$140.23 Million | ▲ +37.2% |
| 2019 | -1.67x | NT$-313.84 Million | NT$188.36 Million | ▲ +52.7% |
| 2018 | -3.52x | NT$-286.71 Million | NT$81.35 Million | ▲ +15.1% |
| 2017 | -4.15x | NT$-250.36 Million | NT$60.30 Million | ▲ +52.7% |
| 2016 | -8.77x | NT$-448.96 Million | NT$51.17 Million | ▼ -70.6% |
| 2015 | -5.14x | NT$-209.24 Million | NT$40.67 Million | ▼ -55.6% |
| 2014 | -3.31x | NT$-128.80 Million | NT$38.97 Million | ▲ +15.0% |
| 2013 | -3.89x | NT$-91.93 Million | NT$23.63 Million | — |